Full-Time

Oncology Account Manager

Confirmed live in the last 24 hours

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilars for healthcare

Compensation Overview

$150k - $200k/yr

Senior

Pittsburgh, PA, USA + 2 more

More locations: Rome, NY, USA | Buffalo, NY, USA

Candidates must reside within Pittsburgh, PA or Buffalo, NY.

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • Strong working knowledge of cancer staging, treatment options, PD1s/checkpoint inhibitors and associated dosing schedules
  • Ability to take customer insights and develop account profiles and business plans for LOQTORZI that drive appropriate use across indications
  • Solid understanding of reimbursement, contracting and finance associated with buy and bill injectable medications
  • Solid analytical, organizational, problem solving, communication and leadership skills required
  • Ability to develop strong relationships with both internal and external customers
  • Knowledge of community oncology practices, hospitals, academic medical centers and IDNs required
Responsibilities
  • Conduct territory business analysis, actively prospect for new business and new opportunities within the territory to engage key HCP stakeholders for LOQTORZI
  • Execute a high level of clinical and product acumen for appropriate positioning of LOQTORZI to meet or exceed sales goal
  • Lead with a patient-centric approach to develop sustained relationships, in targeted accounts, with pertinent clinical staff
  • Represent Coherus and products in a manner consistent with Coherus ethics, policies and compliance expectations at all times
  • Foster teamwork and communication in a high intensity, fast paced environment, where the best interests of patients and Coherus are prioritized
  • Operate independently and with urgency on a daily basis
  • Understand and breakdown complex matrix accounts to ensure proper strategic focus and planning
  • Apply superior selling skills including planning, probing, challenging, aligning, closing and follow-up
  • Plan, budget and execute resources provided by the company including exhibits, speaker programs, the HUB, executive visits, as well as coordination of National Account Director and Key Account Director activities
  • Travel Expectations: Daily in-person and overnight travel can include up to 50% to make in-person visits with HCPs, clinics, and hospitals. Travel will also include National Sales Meetings, Regional Meetings, Speaker Programs and Conferences.
Desired Qualifications
  • Bachelor’s Degree (MBA Preferred)
  • 5 Years minimum, demonstrated sales success in the oncology marketplace preferred
  • Experience in hospital, academic and community oncology selling preferred
  • Prior launch of Oncology injectables preferred
  • Solid understanding of community GPOs (ION, OnMark, USO) as well as Hospital GPOs
  • Understand oncology product distribution (working knowledge)
  • Ability to be flexible, problem-solve and wear multiple hats in a start-up environment

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. The company focuses on research, development, and commercialization of these products, ensuring they meet high quality and efficacy standards set by regulatory authorities. Coherus aims to improve patient lives by expanding access to biologic treatments, helping to offset rising healthcare costs. Their business model allows them to generate revenue through the sale of these cost-effective alternatives, giving them a competitive edge in the biopharmaceutical market.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Launch of Loqtorzi enhances Coherus' position in the oncology biosimilars market.
  • Udenyca wearable injector device could improve patient adherence and market penetration.
  • Collaboration with Cancer Research Institute may lead to innovative cancer treatment combinations.

What critics are saying

  • Sandoz's acquisition of Coherus' biosimilar assets may erode market share.
  • 30% staff reduction could impact operational efficiency and product development timelines.
  • Focus on cancer drugs might divert resources from other biosimilar candidates.

What makes Coherus BioSciences unique

  • Coherus focuses on affordable biosimilars for oncology and inflammatory diseases.
  • The company emphasizes high-quality, cost-effective biologic therapeutics.
  • Coherus' pipeline includes innovative biosimilar candidates in immunology and ophthalmology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ETF Daily News
Mar 29th, 2025
Intech Investment Management LLC Makes New $38,000 Investment in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Intech Investment Management LLC makes new $38,000 investment in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Stock Titan
Feb 24th, 2025
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus BioSciences (NASDAQ: CHRS) has announced its senior management's upcoming participation in the 45th Annual TD Cowen Health Care Conference.

PE Hub
Jul 3rd, 2024
SK Capital's Apotex to acquire Canadian rights to Toripalimab

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences.

TipRanks
Jun 5th, 2024
Coherus Biosciences Appoints Rita Karachun to Board

Coherus Biosciences appoints Rita karachun to board.

GlobeNewswire
Jun 5th, 2024
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences appoints Rita Karachun, CPA, CGMA to its Board of Directors.